Yongsheng Li

机构：Chongqing University, China Tobacco, First People's Hospital of Yunnan Province, Shanghai Shipbuilding Technology Research Institute, Chongqing University of Education, China Coal Technology and Engineering Group Corp (China), Chongqing Cancer Hospital, Chongqing Science and Technology Commission, China State Shipbuilding (China), Chongqing Medical University · ORCID：0000-0003-2175-9449

发表论文 498 篇 · 总被引 22665 次 · h-index 71

代表论文

• CD39 and CD73: biological functions, diseases and therapy (2025 · Molecular Biomedicine · 被引 27)
• Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials (2025 · 癌症：英文版 · 被引 12)
• Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8 + T cells (2025 · Journal for ImmunoTherapy of Cancer · 被引 9)
• The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study (2025 · Annals of Oncology · 被引 9)
• Cholesterol 25‐Hydroxylase Enhances Myeloid‐Derived Suppressor Cell (MDSC) Immunosuppression via the Stimulator of Interferon Genes (STING)‐Tank‐Binding Kinase 1 (TBK1)‐Receptor‐Interacting Protein Kinase 3 (RIPK3) Pathway in Colorectal Cancer (2025 · MedComm · 被引 6)
• From Bench to Bedside: Emerging Paradigms in CAR‐T Cell Therapy for Solid Malignancies (2025 · Advanced Science · 被引 6)